Mr. Todd Shapiro reports

RHELION LIFE SCIENCES' WHOLLY OWNED SUBSIDIARY FILAMENT HEALTH TO SUPPLY BELGIUM'S FIRST PSILOCYBIN COMPASSIONATE USE PROGRAM, TO HELP OPEN THE DOOR TO PATIENT ACCESS FOR TREATMENT-RESISTANT DEPRESSION

Rhelion Life Sciences Corp.'s wholly owned subsidiary Filament Health Corp. has entered into a supply and licensing agreement with Epsylon ASBL, a Belgian non-profit association operating psychiatric hospitals, for the supply of PEX010 to the program titled "Compassionate use program with psilocybin (PEX010) for the treatment of treatment resistant depression." The program is supported by the Psychedelic Society Belgium, a non-profit association that advocates for regulated access to psychedelic-assisted therapy in Belgium and has contributed its expertise in psychedelic-assisted therapy to the program. PSBE has no financial or commercial relationship with Rhelion or Filament.

Psilocybin is currently available in Belgium only within clinical trials. Belgian law allows a compassionate use program to give patients with a serious condition and no satisfactory authorized treatment access to a medicine that is not yet authorized, outside of a clinical trial. Each program is tied to one specific medicinal product and must be approved by the Federal Agency for Medicines and Health Products. This program is for PEX010: Once approved, it will give patients with treatment-resistant depression access to psilocybin treatment with Filament's drug candidate.

The program is led by Dr. Daniel Souery at Epsylon. Epsylon is the applicant for the program. Filament is not responsible for the conduct of the program.

"Access to psilocybin treatment is growing across Europe, and Belgium is now part of that shift," said Todd Shapiro, chief executive officer and director of Rhelion. "We hope programs like this one show regulators in Europe and around the world that patients with serious unmet needs can be given safe, regulated access to natural psilocybin."

PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. PEX010 is available in a standardized dosing range of one, five and 25 milligrams from a single drug candidate, with a 0.5-milligram dose to follow, produced using Filament's proprietary and patented extraction, purification and stabilization methods, giving investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the company completed its previously announced acquisition of Filament Health, including its lead drug candidate, PEX010, and its portfolio of 78 issued patents across 13 patent families.

About Rhelion Life Sciences Corp.

Rhelion Life Sciences is a science- and research-led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health, the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.

We seek Safe Harbor.